• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Stalking a Speculative Trade in Alkermes

The longer-term weekly chart is ugly, but optimistic in the near-term.
By TIMOTHY COLLINS
Apr 14, 2016 | 11:43 AM EDT
Stocks quotes in this article: ALKS

This isn't what you would call a banner 2016 for Alkermes (ALKS). Disappointment in the top-line results from a depression drug have cut shares in half this year, but the tide looks like it may be turning. Bulls are starting to sniff the stock again. It's possible things come back around for the depression drug as it can be a bit more difficult to measure versus something like a tumor. This isn't a one-trick pony. Revenue is still expected to grow in the 10% to 20% range next year, although the company will still be in the red. Biotech names will often run in anticipation, and it's looking like some buyers might be bottom-fishing here.

If we simply look at pure price on the daily chart, the clarity of importance around this $40 level is easy to see. This was the gap -- nay, the crater -- left in the wake of the January disappointment. It's clear there has been no action between $40 and $58 when we look to the left of the chart at the volume by price. This creates the potential for a vacuum. It also represents the possibility of volatility in the air pocket. There won't be a recent past to glean information for trading, but we do know $40 will become support, as well as the current bull flag highlighted in yellow. Given the $10 move in the recent bullish channel, the minimum upside expectation here is $43.33 with a high side of $50. This is one where I don't expect the gap to be filled in the near term, but $3 to $5 is a very reasonable expectation.

The longer-term weekly chart is just as ugly in retrospect, but also optimistic in the near-term. Note how we see the same $40 resistance level, but now we can trace it back to 2014. That lends credence to the thesis that a move to about $40 could give a kick higher. We're seeing a bullish cross on the MACD, the five-week simple moving average (SMA) has crossed above the 13-week SMA as well. The full stochastics has already crossed over bullish and did so while oversold. It's now pushed over $50, which has been a positive sign in the past.

Finally, the StochRSI is very strong, along with the Chaikin Oscillator, so momentum and volume appear to be working. A longer-term trend has to be willing to give this $5 or even $10 to the downside, so it can't be seen as anything other than a small, aggressive position; however, there is a $10 to $15 upside over the next six to 12 months against a smaller downside and a lot of pessimism already factored into the name.

I'm taking a small, speculative long position with the idea of a swing trade at the very minimum. I would take profits into $45 no matter the timeframe; however, if we do nothing over the next few weeks I'll look to use the 13-week SMA as a stop.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Collins was long ALKS, although positions may change at any time.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Moderna Now Looks Like an Effective Long Trade With Few Side Effects

Bruce Kamich
Jan 14, 2021 12:06 PM EST

MRNA has corrected its big November rally and now looks ready to start a fresh advance, according to the charts.

Pacific Biosciences Reaches Our Price Target: Now What?

Bruce Kamich
Jan 13, 2021 12:19 PM EST

Let's check out the charts and technical indicators.

Emergent BioSolutions Is Looking Stronger

Bruce Kamich
Jan 12, 2021 10:37 AM EST

Here's an update on EBS shares.

Danaher Could Trade Higher

Bruce Kamich
Jan 11, 2021 2:50 PM EST

I do not find enough technical reasons to recommend new long positions at this point in time.

Here's Why Eli Lilly Broke to the Upside

Bruce Kamich
Jan 11, 2021 1:00 PM EST

Let's review the charts and indicators.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • 08:35 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 1/13/2021

    Lower highs... SPX (Long-Term View) The 1/8/2...
  • 08:07 AM EST GARY BERMAN

    Tuesday Morning Fibocall for 1/12/2021

    Watch if the recent trend of lower highs continues...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login